Compare

CJC-1295 (no DAC) vs Larazotide

Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.

Last reviewed . By the PeptIQ team.

Observational reporting only — not medical advice. Does not recommend doses, protocols, or treatments.

CJC-1295 (no DAC)

265 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 49% · Mixed 42% · Unfavorable overall 9%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Recovery
8
Digestive comfort
-56
Skin appearance
-87
Appetite control
-91
Energy
-1

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Anxiety
-76
Flushing
-157
Headache
-122
GI discomfort
-95
Dizziness
-2

Self-reported dose per injection

Median bucket: 0.4–0.6 mg · Most common: 0.2–0.4 mg

Reports span 0.05–2 mg

0.05–0.1 mg
2
0.1–0.2 mg
13
0.2–0.4 mg
17
0.4–0.6 mg
13
0.6–1 mg
8
1–2 mg
2

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Common discussion topics

timing29stacking37side effects15cjc-1295 (no dac)23

How repeat users are trending

Among repeat reporters, 59% said they felt similar to their last entry, 35% more positive, and 19% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 27 days · Based on 58 repeat reporters

Larazotide

1343 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 47% · Mixed 34% · Unfavorable overall 19%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Energy
-14
Mood
-82
Focus
-135
Sleep quality
-142
Lean mass
-143

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Dizziness
-98
Fatigue
-2
Nausea
10
Water retention
-146
Appetite loss
-143

Self-reported dose per injection

Median bucket: 1–2 mg · Most common: 0.6–1 mg

Reports span 0.1 to ≥ 5 mg (open-ended top bucket)

0.1–0.2 mg
5
0.2–0.4 mg
15
0.4–0.6 mg
19
0.6–1 mg
29
1–2 mg
24
2–3 mg
13
3–5 mg
9
5+ mg
3

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Common discussion topics

timing27stacking10side effects13larazotide26

How repeat users are trending

Among repeat reporters, 57% said they felt similar to their last entry, 45% more positive, and 17% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 28 days · Based on 295 repeat reporters

Sources (6)

Published sources linked on the CJC-1295 (no DAC) and Larazotide wiki pages.

  1. PubMed

    Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting GH-releasing hormone analog

    Teichman SL, Neale A, Lawrence B, et al. J Clin Endocrinol Metab. 2006

    Source
    Wiki study page →
  2. PubMed

    Growth hormone-releasing peptides: clinical applications

    Ghigo E, Arvat E, Camanni F. Endocrine. 2008

    Source
    Wiki study page →
  3. PubMed

    Advances in the detection of growth hormone releasing hormone synthetic analogs

    Memdouh S, Gavrilović I, Ng K, et al. Drug testing and analysis. 2021

    Source
    Wiki study page →
  4. PubMed

    Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet

    Leffler DA, Kelly CP, Abdallah HZ, et al. Gastroenterology. 2015

    Source
    Wiki study page →
  5. PubMed

    Coeliac disease and the intestinal barrier: mechanisms of disruption and strategies for restoration

    Damianos JA, Bledsoe A, Camilleri M, et al. Gut. 2026

    Source
    Wiki study page →
  6. PubMed

    The potential utility of tight junction regulation in celiac disease: focus on larazotide acetate

    Khaleghi S, Ju JM, Lamba A, et al. Therapeutic advances in gastroenterology. 2016

    Source
    Wiki study page →